 SAN DIEGO, Sept. 27, 2021 GLOBE NEWSWIRE -- Cidara Therapeutics, Inc. NASDAQ: CDTX, a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data on rezafungin clinical safety and pharmacokinetics in people with hepatic impairment, at IDWeek taking place virtually from September 29-October 3, 2021. 